Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023

MENLO PARK, Calif.–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023. Operational & Corporate Updates Our operational progress with ivonescimab (SMT112), an innovative, potentially…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks